Notice - Prescription Drug List (PDL): Lovastatin

Notice - Prescription Drug List (PDL): Lovastatin The purpose of this Notice of Amendment is to announce the revised listing for lovastatin on the Prescription Drug List (PDL). As stated in the Notice of Intent to Amend, posted June 4, 2014, the revision will allow lovastatin to be marketed as a nonprescription product. Only the Human part of the PDL has been revised. 2023-09-29 Health Canada open-ouvert@tbs-sct.gc.ca Health and SafetyLovastatinnoticenotice of amendmentprescription drug listPDLrevised listingnonprescription statushuman useHuman Prescription Drug-ListVeterinary use unchanged Notice - Prescription Drug List (PDL): LovastatinHTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notice-lovastatin.html Notice - Prescription Drug List (PDL): LovastatinHTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/liste-drogues-ordonnance/liste-lovastatine.html

The purpose of this Notice of Amendment is to announce the revised listing for lovastatin on the Prescription Drug List (PDL). As stated in the Notice of Intent to Amend, posted June 4, 2014, the revision will allow lovastatin to be marketed as a nonprescription product. Only the Human part of the PDL has been revised.

Data and Resources

Similar records